Veradermics Highlights VDPHL01 Efficacy in Direct Comparisons to Minoxidil

Event summary

  • Veradermics presented two E-posters at the 2026 Music City SCALE Symposium comparing VDPHL01's Phase 2 male data to existing minoxidil formulations.
  • The first poster involved a blinded, retrospective investigator global assessment by nine dermatologists.
  • The second poster used AI-based Global HairMap™ to compare VDPHL01 outcomes against immediate-release oral minoxidil.
  • VDPHL01 is in Phase 3 development as an oral, non-hormonal treatment for pattern hair loss with patent protection until 2043.

The big picture

Veradermics is positioning VDPHL01 as a next-generation treatment for pattern hair loss, a market with no new FDA-approved prescription medicines in nearly 30 years. The direct comparisons to existing minoxidil formulations aim to establish VDPHL01's efficacy and safety advantages, potentially transforming the treatment landscape for androgenetic alopecia. The company's focus on oral, non-hormonal solutions addresses a significant unmet need in a market projected to reach $30B by 2028.

What we're watching

Clinical Validation
Whether the direct comparisons will position VDPHL01 as a superior alternative to existing minoxidil treatments.
Regulatory Pathway
The pace at which Veradermics advances VDPHL01 through Phase 3 trials and potential FDA approval.
Market Differentiation
How Veradermics leverages the extended-release technology to capture market share in the $30B aesthetics market.